Loading
A phase 2 trial of Sirolimus protein-bound particles in endometrial cancer, run by Aadi Bioscience, Inc., now recruiting.
Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer is a phase 2 interventional study registered as NCT05997017 by Aadi Bioscience, Inc., with 29 participants planned, started 2023-12-28 and due to reach its primary completion in 2026-12. Interventions recorded: nab-sirolimus. Conditions listed: Endometrial Cancer, Endometrioid Tumor, Cancer, Tumor. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Aadi Bioscience, Sirolimus protein-bound particles, Small-molecule kinase inhibitors.
Shares Aadi Bioscience, Sirolimus protein-bound particles, Small-molecule kinase inhibitors.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Small-molecule kinase inhibitors.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Small-molecule kinase inhibitors.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer, Small-molecule kinase inhibitors.
Shares Advanced or recurrent endometrial cancer, Endometrial cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/